Weekly Recap | Abbvie +0.26%, most brokers rate it buy
I'm LongbridgeAI, I can summarize articles.AbbVie (ABBV) rose 0.26% this week to close at $257.12, while the S&P 500 fell 0.8%, leaving the stock about 1.06 percentage points ahead. It was a back-loaded week: Tuesday opened at $251.84 and marked the week’s low of $246.77, then the stock climbed for three straight sessions, finishing Friday just under the week’s high of $259.61. The weekly range was 5.1%. Volume was subdued, with average daily turnover about 13% below the 60-day median.
The Week
AbbVie (ABBV) rose 0.26% this week to close at $257.12, while the S&P 500 fell 0.8%, leaving the stock about 1.06 percentage points ahead. It was a back-loaded week: Tuesday opened at $251.84 and marked the week’s low of $246.77, then the stock climbed for three straight sessions, finishing Friday just under the week’s high of $259.61. The weekly range was 5.1%. Volume was subdued, with average daily turnover about 13% below the 60-day median.
Key Events
The main company news this week ran along two tracks: pipeline updates and dividend announcements. On 10 September, AbbVie presented SKYRIZI and RINVOQ growth along with pipeline catalysts at the Wells Fargo Conference. The same day brought positive late-stage data for its menstrual migraine treatment. Later that day and into Friday, the company declared a quarterly dividend of $1.73 per share. Position changes were notable too: UBS AM purchased 106,091 shares, and billionaire Israel Englander more than doubled his stake, alongside several mid-sized institutions adding new positions.
Analyst Ratings
Coverage totals 31 institutions. Among them, 17 rate it buy, 8 overweight, 5 hold, 1 underweight, and 0 sell. The consensus rating is buy, with a consensus target of $277.31, about 7.85% above the current price. The target range runs from $200 to $328, pointing to wide dispersion. The stock ranks 4th within the biotech industry group.
The Week Ahead
Macro data dominates the coming week. Wednesday, 16 September, brings retail sales, retail sales ex-autos, and retail control, alongside the New York Fed manufacturing index, NAHB housing market index, import prices, and EIA crude inventories. If retail sales miss the expected 0.9% gain, defensive healthcare could benefit on relative basis, putting the dividend appeal of ABBV to the test.
In Short
AbbVie beat the broader market this week, with both pipeline progress and dividend news adding substance. The rating backdrop skews positive, but the target range is wide and trading activity ran below recent norms. The latest session’s flow shows large and mid-sized lot net buying, with retail flows relatively muted, matching interest in high-dividend healthcare names. The key to watch now is how healthcare performs relative to the market after next week’s retail data, and whether the flow picture holds.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.